VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
Part of paid clinical trials in Cleveland, Ohio.
- Sponsor
- The Cleveland Clinic
- Study ID
- NCT00274794
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- filgrastim — BIOLOGICAL10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
- rituximab — BIOLOGICAL375 mg/m2, IV, Once per week for 3 weeks.
Study Details
RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, or chemotherapy, such as etoposide, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant. Giving etoposide and G-CSF together with rituximab before a peripheral stem cell transplant may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This randomized clinical trial is studying how well giving etoposide and G-CSF with or without rituximab works in treating patients who are undergoing an autologous peripheral stem cell transplant for B-cell non-Hodgkin's lymphoma.
Key Dates
- Start date
- Feb 29, 2000
- Status verified
- Mar 2011
- Primary completion
- May 31, 2006
- Completion
- May 31, 2006
Study Design
- Enrollment
- 55 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Other: Rituxan + Etoposide + G-CSF
- Other: Etoposide + G-CSF
Primary Outcome Measure
Correlate CD34+ cell yields with the addition of rituximab [ Time Frame: At least two weeks prior to transplant ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cleveland Clinic Taussig Cancer Institute | Cleveland | Ohio | 44195 | - |
Find similar trials in Cleveland, OH
Related Studies
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyPHASE2 · Recruiting · Spectrum Pharmaceuticals, Inc · Valhalla, New York
- Long-Term Follow-up StudyEnrolling By Invitation · Caribou Biosciences, Inc. · Birmingham, Alabama
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruiting · Adela, Inc · Duarte, California